* SAGE Therapeutics Inc reported a quarterly adjusted loss of $1.53​​ per share for the quarter ended January 1, higher than the same quarter last year, when the company reported EPS of $-3.37. The mean expectation of nineteen analysts for the quarter was for a loss of $1.53 per share. Wall Street expected results to range from $-1.74 to $-1.20 per share.

* Revenue rose 337.1% to $11.87 million from a year ago; analysts expected $10.80 million.

* SAGE Therapeutics Inc's reported EPS for the quarter was a loss of $1.53​.

* The company reported a quarterly loss of $93.55 million.

* SAGE Therapeutics Inc shares had risen by 18.3% this quarter and lost 60.6% so far this year.

FORECAST CHANGES

* The mean earnings estimate of analysts had risen by about 0.5% in the last three months.​

* In the last 30 days, two analysts negatively revised earnings estimates

RECOMMENDATIONS

* The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy," 16 "hold" and 2 "sell" or "strong sell."

* The average consensus recommendation for the biotechnology & medical research peer group is also "hold"

Wall Street's median 12-month price target for SAGE Therapeutics Inc is 10.00 This summary was machine generated from LSEG data October 30 at 02:51 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,

MISSED

Sep. 30 2024 -1.53 -1.53 Met

Jun. 30 2024 -1.66 -1.70 Missed

Mar. 31 2024 -1.65 -1.80 Missed

Dec. 31 2023 -1.28 -1.80 Missed